SOURCE: CDEX , Inc.

June 07, 2007 09:00 ET

CDEX, Inc. Announces Expansion of Its ValiMed™ Medication Validation System Product Line

TUCSON, AZ--(Marketwire - June 7, 2007) - CDEX, Inc. (OTCBB: CEXI) announces the expansion of its ValiMed™ Product Line to allow greater cost accessibility for the full spectrum of medical care facilities. The ValiMed™ expansion includes more robust and sensitive medication signature recognition software and an expanded Medication Signature Library.

"With the enhanced ValiMed™ unit and the addition of a QA audit capability for monitoring pharmacy compounding practices," said Pam Price, Senior Vice President of Sales and Service for Baxa Corporation, the exclusive distributor of the ValiMed™ System, "our sales force is excited about and aggressively introducing ValiMed™ technology to our customers."

Using Enhanced Photoemission Spectroscopy, ValiMed™ quickly validates high-risk medication admixtures, as well as returned narcotics to provide an increased level of patient safety. ValiMed™ compares a medication's spectroscopic signature to the Medication Signature Library and returns an easy to understand "validated" or "not validated" result, requiring no user interpretation. CDEX is continuing to build its signature library, which currently contains over 70 unique pharmaceutical signatures and is expected to grow to over 150 by the end of 2007.

"Our expanded ValiMed™ solution provides greater functionality and detection sensitivity that we believe brings true value to our clients and a higher level of safety to patients at healthcare facilities," said Malcolm Philips, Founding CEO and Chairman of the Board. "This expanded product line allows CDEX to provide a ValiMed™ Unit that addresses medication validation needs of most medical care facilities, not just the mega hospitals. Today, we have a backlog of clients that are awaiting installation of expanded ValiMed™ units and we are preparing to start that delivery process."

About CDEX, Inc.

CDEX, Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (I) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (II) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is a CDEX solution for the healthcare market. Corporate headquarters and research and development facilities for CDEX are located in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact CDEX, Inc. at 520.745.5172 or cdexmanagement@cdex-inc.com.

About Baxa Corporation

Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for fluid handling and delivery. Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of fluid medications. Key Automated Syringe Fillers, Exacta-Med products include Rapid-Fill™® Oral Dispensers, MicroFuse® Syringe Infusers, Repeater™ Pharmacy Pumps, and Exacta-Mix™ and MicroMacro™ Multi-Source Automated Compounders; used worldwide in hospitals and healthcare facilities. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada and the United Kingdom; direct representation in Austria, Belgium, Denmark, Finland, France, Germany, Luxembourg and The Netherlands; and distribution partners worldwide. Further information is available at www.baxa.com.

Any statements made in this press release, which contain information that is not historical, are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

Contact Information